{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"413.333","value":"137.78"},{"groupId":"OG001","spread":"110.333","value":"36.78"},{"groupId":"OG002","spread":"0.000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"589.458","value":"602.56"},{"groupId":"OG001","spread":"564.095","value":"433.89"},{"groupId":"OG002","spread":"758.482","value":"772.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"592.060","value":"660.78"},{"groupId":"OG001","spread":"497.727","value":"381.34"},{"groupId":"OG002","spread":"541.778","value":"689.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"277.976","value":"796.67"},{"groupId":"OG001","spread":"550.083","value":"809.50"},{"groupId":"OG002","spread":"1111.764","value":"1075.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.834","value":"137.62"},{"groupId":"OG001","spread":"52.716","value":"124.53"},{"groupId":"OG002","spread":"88.967","value":"198.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG000","spread":"NA","value":"125.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"},{"groupId":"OG001","spread":"0.000","value":"0.00"},{"groupId":"OG002","spread":"25.948","value":"13.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"CYCLE 1 DAY 15, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"},{"groupId":"OG001","spread":"0.000","value":"0.00"},{"groupId":"OG002","spread":"0.000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"},{"groupId":"OG001","spread":"0.000","value":"0.00"},{"groupId":"OG002","spread":"0.000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"494.302","value":"480.13"},{"groupId":"OG001","spread":"239.605","value":"372.25"},{"groupId":"OG002","spread":"153.035","value":"319.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"},{"groupId":"OG001","spread":"0.000","value":"0.00"},{"groupId":"OG002","spread":"0.000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1622.007","value":"1128.67"},{"groupId":"OG001","spread":"550.129","value":"548.00"},{"groupId":"OG002","spread":"408.512","value":"393.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"0.00"},{"groupId":"OG002","spread":"0.000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"773.029","value":"677.67"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"194.00"},{"groupId":"OG002","spread":"100.416","value":"231.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.00"},{"groupId":"OG002","spread":"0.000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"229.173","value":"242.95"},{"groupId":"OG002","spread":"190.919","value":"277.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"258.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.174","value":"19.79"},{"groupId":"OG001","spread":"123.037","value":"43.50"},{"groupId":"OG002","spread":"48.173","value":"19.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"END OF TREATMENT (~194 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 10 mg/kg isatuximab, given 1 hour after belantamab mafodotin end of infusion (EOI), administered as an IV infusion once weekly (Q1W) for 5 doses, then every 2 weeks (Q2W), and thereafter on day 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab"},{"description":"Participants with RRMM received 1.4 mg/kg of belantamab mafodotin IV infusion, once every 8 weeks (Q8W) infused over 30- 60 minutes on day 1 of each 56 day cycle in combination with 10 mg/kg isatuximab, given 1 hour after belantamab mafodotin EOI administered as an IV infusion once weekly (Q1W) for 5 doses, then every 2 weeks (Q2W) and thereafter on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG001","title":"1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab"},{"description":"Participants with RRMM received 1.9 mg/kg of belantamab mafodotin IV infusion, Q8W infused over 30- 60 minutes on day 1 of each 56 day cycle in combination with 10 mg/kg isatuximab, given 1 hour after belantamab mafodotin EOI administered as an IV infusion once weekly (Q1W) for 5 doses, then every 2 weeks (Q2W) and thereafter on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG002","title":"1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab"}],"paramType":"MEAN","populationDescription":"PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The \"0\" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"Predose, end of infusion (EOI), and 2-hour and 24-hour postdose on Cycle 1 Day 1; predose on Cycle 1 Days 8, 15 and 22, anytime samples on C1D8 and C1D22 ; predose and EOI on Day 1 of Cycles 2, 4, 6, 9 and 12; and end of treatment (~194 weeks).","title":"DE Phase: Plasma Concentration of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"Picogram / millilitre (pg/mL)"}